Alnylam Pharma (DUL) Stock Statistics & Valuation Metrics

Alnylam Pharma has a market cap or net worth of CHF22.24B. The enterprise value is CHF41.31K.

Alnylam Pharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Alnylam Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 13.74%.

The current PE Ratio of Alnylam Pharma is 33.7. Alnylam Pharma’s PEG ratio is -0.79.

In the last 12 months, Alnylam Pharma had revenue of 3.71B and earned 313.75M in profits. Earnings per share was 2.39.

In the last 12 months, operating cash flow was 634.49M and capital expenditures -91.95M, giving a free cash flow of 542.54M billion.

Alnylam Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Alnylam Pharma upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).

Alnylam Pharma as a current ratio of 2.76, with Debt / Equity ratio of 93.60%

In the past 12 months, Alnylam Pharma has paid 9.40M in taxes.

Alnylam Pharma EV to EBITDA ratio is 81.90, with an EV/FCF ratio of 111.12.

Alnylam Pharma has CHF3.31B in cash and marketable securities with CHF1.27B in debt, giving a net cash position of CHF2.04B billion.

Gross margin is 79.72%, with operating margin of 13.51%, and net profit margin of 8.45%.

The average price target for Alnylam Pharma is CHF301.37, which is 11.43% higher than the current price. The consensus rating is Strong Buy